In July 2026, Research Power Inc. was in London with the AstraZeneca Hem-Oncology UK leadership and Key Account Management team focused on advancing the care of patients living with B-cell malignancies. Over the course of 2 days, RPI worked with the UK team in reviewing and discussing the key data presented at the European Hematology Association Congress meeting in Stockholm, Sweden in June and how the body of evidence and EHA Guideline recommendations can inform best patient care in clinical practice with a focus on CLL. Through a series of presentations and workshops, the UK Team left feeling invigorated and equipped to elevate customer conversations and enhance the care of patients living with CLL.